ANALISIS ADVERSE DRUG REACTIONS OBAT ANTI RETROVIRAL PADA PENGOBATAN PASIEN HIV/AIDS DI RSUD GUNUNG JATI CIREBON TAHUN 2013
DOI:
https://doi.org/10.12928/pharmaciana.v6i1.3327Keywords:
HIV/AIDS, Anti Retroviral (ARV), Adverse Drug Reaction (ADR)Abstract
Acquired Immunodeficiency Syndrome (AIDS) is a disease caused by infection with Human Immunodeficiency Virus (HIV). The pharmacology treatment for the infection was antiretroviral therapy. The problem from the use of antiretroviral drugs (ARV) is the emergence of unwanted drug reactions (adverse drug reaction). The purpose of this study was to identify and analyze the incidence of adverse drug reactions from the use of antiretroviral drugs in the treatment of patients with HIV / AIDS that occurred in RSUD Gunung Jati Cirebon. This study involves 122 patients. Data were obtained from medical records and patient interview form. The data were evaluated with a descriptive analysis of demographic profile of patients and the percentage of adverse drug reaction (ADR) The results showed an adverse drug reaction (ADR) on the use of antiretroviral drugs in the treatment of patients with HIV / AIDS in RSUD Gunung Jati Cirebon. ARV regimens are the most widely used is the combination of Zidovudine + Lamivudine + Nevirapine / Efavirenz (AZT + 3TC + EFV) as much as 31.2% (38 people). Duration of therapy ARV in Seroja Clinic RSUD Gunung Jati Cirebon most is> 2 years - 4 years 28.7% (35 people). Types of adverse drug reaction (ADR), which occurs in the use of antiretroviral drugs in the treatment of patients with HIV / AIDS in RSUD Gunung Jati Cirebon include: headache (22.1%), fatigue (6.8%), anemia (9.3%), itching (14.4%), nausea / vomiting (20.1%), diarrhea (7.2%), lipodystrophy (2.0%), rash (11.3%), skin discoloration (1.6%), neuropathy (1.6%) and sleep disorders (3.6%).Downloads
Published
2016-04-14
Issue
Section
Clinical and Community Pharmacy
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.